Chris Schott
Stock Analyst at JP Morgan
(3.53)
# 783
Out of 4,842 analysts
128
Total ratings
56.47%
Success rate
2.52%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $17.53 | +31.20% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $132.75 | +31.83% | 4 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,100 → $1,000 | $605.39 | +65.18% | 6 | Mar 31, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $111.11 | +17.00% | 5 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $7.30 | +64.38% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $185.62 | +7.75% | 2 | Nov 13, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $515.55 | +11.53% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $167.14 | +37.61% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $722.57 | +52.23% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $9.54 | +109.64% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $27.13 | +51.12% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $32.64 | +28.68% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $283.54 | -4.78% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $23.45 | +44.99% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $76.40 | +63.61% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $8.83 | +58.55% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.80 | +1,271.57% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $13.52 | +47.93% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.61 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $47.85 | +63.01% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $3.84 | +24,639.58% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.48 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.93 | +92.83% | 3 | Nov 2, 2018 |
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $17.53
Upside: +31.20%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $132.75
Upside: +31.83%
Regeneron Pharmaceuticals
Mar 31, 2025
Maintains: Overweight
Price Target: $1,100 → $1,000
Current: $605.39
Upside: +65.18%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $111.11
Upside: +17.00%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.30
Upside: +64.38%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $185.62
Upside: +7.75%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $515.55
Upside: +11.53%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $167.14
Upside: +37.61%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $722.57
Upside: +52.23%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.54
Upside: +109.64%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $27.13
Upside: +51.12%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $32.64
Upside: +28.68%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $283.54
Upside: -4.78%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $23.45
Upside: +44.99%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $76.40
Upside: +63.61%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $8.83
Upside: +58.55%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.80
Upside: +1,271.57%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $13.52
Upside: +47.93%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.61
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $47.85
Upside: +63.01%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $3.84
Upside: +24,639.58%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.48
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.93
Upside: +92.83%